Patents by Inventor Jeffrey Neitz
Jeffrey Neitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230202974Abstract: Disclosed herein, inter alia, are compounds and methods for inhibiting Caspase 6 and the treatment of diseases, pharmaceutical composition including a compound as described herein and a pharmaceutically acceptable excipient and methods of inhibiting human Caspase 6 protein activity, the method including: contacting the human Caspase 6 protein with a compound as described herein.Type: ApplicationFiled: November 20, 2020Publication date: June 29, 2023Inventors: Adam R. Renslo, Michelle R. Arkin, R. Jeffrey Neitz, Raymond Ng, Peter Lee
-
Publication number: 20230142739Abstract: Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.Type: ApplicationFiled: April 2, 2021Publication date: May 11, 2023Inventors: Michelle R. Arkin, Lucas Brunsveld, Christian Ottmann, Adam R. Renslo, R. Jeffrey Neitz, Mengqi Zhong, Kenneth K. Hallenbeck, Priyadarshini Jaishankar, Shubhankar Dutta, John K. Morrow, Eline Sijbesma, Bente Aminhan Somsen, Galen Patrick Miley, Emira Josien Visser, Peter James Cossar, Madita Wolter, Thorsten Genski, Laura Mariana Levy, Torsten Hoffmann, Dimitrios Tzalis, Dario Valenti, Markella Konstantinidou
-
Publication number: 20230052528Abstract: Disclosed herein, inter alia, are compounds and methods for inhibiting Taspase1 and the treatment of cancer.Type: ApplicationFiled: November 20, 2020Publication date: February 16, 2023Inventors: Michelle R. Arkin, R. Jeffrey Neitz, Adam R. Renslo, James Hsieh, Shubhankar Dutta, Clifford Bryant, William J. Moore, Alex G. Waterson, Lidia Sambucetti, Somnath Jana, lan M. Romaine, Alexander P. Lamers, Yassir Younis Adam, Claire Repellin
-
Publication number: 20220112179Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: ApplicationFiled: December 20, 2021Publication date: April 14, 2022Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human Servi, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
-
Publication number: 20220081427Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: November 11, 2021Publication date: March 17, 2022Applicant: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
-
Patent number: 11247985Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: GrantFiled: January 21, 2020Date of Patent: February 15, 2022Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the U.S. Department of Hearth and Human Services, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
-
Publication number: 20200277285Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: May 12, 2020Publication date: September 3, 2020Applicant: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
-
Publication number: 20200157082Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: ApplicationFiled: January 21, 2020Publication date: May 21, 2020Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
-
Patent number: 10633370Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: GrantFiled: October 20, 2016Date of Patent: April 28, 2020Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the U.S. Department of Health and Human Services, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
-
Publication number: 20200039972Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: October 15, 2019Publication date: February 6, 2020Applicant: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
-
Publication number: 20190194176Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: February 28, 2019Publication date: June 27, 2019Applicant: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
-
Publication number: 20180319780Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: July 19, 2018Publication date: November 8, 2018Applicant: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRAD!, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
-
Publication number: 20180037577Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: October 18, 2017Publication date: February 8, 2018Applicant: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
-
Patent number: 9884828Abstract: The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.Type: GrantFiled: May 21, 2012Date of Patent: February 6, 2018Assignee: Imago Pharmaceuticals, Inc.Inventors: Danielle L. Aubele, Albert W. Garofalo, Simeon Bowers, Anh P. Truong, Xiaocong Michael Ye, Maurizio Franzini, Marc Adler, R. Jeffrey Neitz, Gary Probst
-
Patent number: 9796706Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: GrantFiled: December 27, 2016Date of Patent: October 24, 2017Assignee: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. Sham, Roy K. Hom, Andrei W. Konradi, Gary D. Probst, Simeon Bowers, Anh Truong, R. Jeffrey Neitz, Jennifer Sealy, Gergely Toth
-
Publication number: 20170107209Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: December 27, 2016Publication date: April 20, 2017Applicant: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. SHAM, Roy K. Hom, Andrei W. Konradi, Gary D. Probst, Simeon Bowers, Anh Truong, R. Jeffrey Neitz, Jennifer Sealy, Gregely Toth
-
Publication number: 20150259330Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: May 29, 2015Publication date: September 17, 2015Applicant: IMAGO PHARMACEUTICALS, INC.Inventors: Hing L. SHAM, Roy K. HOM, Andrei W. KONRADI, Gary D. PROBST, Simeon BOWERS, Anh TRUONG, R. Jeffrey NEITZ, Jennifer SEALY, Gergely TOTH
-
Patent number: 9073891Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: GrantFiled: September 14, 2012Date of Patent: July 7, 2015Assignee: Imago Pharmaceuticals, Inc.Inventors: Hing L. Sham, Roy K. Hom, Andrei W. Konradi, Gary D. Probst, Simeon Bowers, Anh Truong, R. Jeffrey Neitz, Jennifer Sealy, Gergely Toth
-
Publication number: 20150126502Abstract: The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.Type: ApplicationFiled: January 14, 2015Publication date: May 7, 2015Inventors: Robert A. GALEMMO, Dean R. ARTIS, Xiaocong Michael YE, Danielle Aubele, Anh TRUONG, Simeon BOWERS, Roy K. Hom, Yong-Liang ZHU, R. Jeffrey NEITZ, Jennifer SEALY, Marc ADLER, Paul BEROZA, John P. ANDERSON
-
Publication number: 20140329863Abstract: Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease.Type: ApplicationFiled: February 26, 2014Publication date: November 6, 2014Applicant: The Regents of the University of CaliforniaInventors: Adam R. Renslo, Alejandra Gallardo-Godoy, Michael B. Silber, Stanley B. Prusiner, Kurt Giles, Zhe Li, R. Jeffrey Neitz